Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis Article

International Collaboration

cited authors

  • Meier, Juris J.; Bardtrum, Lars; Cheng, Alice Y. Y.; Malling, Brian; Montanya, Eduard; Wagner, Lily; Pratley, Richard E.

authors

Publication Date

  • January 17, 2023

webpage

published in

category

keywords

  • GLP-1 analogue
  • incretin therapy
  • phase 3 study
  • type 2 diabetes

start page

  • 1130

end page

  • 1135

volume

  • 25

issue

  • 4